FDA-cleared profile

Cydar EV (Series B) and Cydar EV Maps

Cydar Ltd. · Fluoroscopy/Angiography · FDA-cleared (510(k))

Authorized purpose: Cydar EV and Cydar EV Maps support the labeled endovascular workflow by processing and displaying patient-specific vascular imaging and maps for trained procedural professionals under direct clinical control.

Clinical role
Image registration, fusion, localization, or procedural guidance under direct professional control.
Images and patients
Fluoroscopy/Angiography · Peripheral vascular and endovascular anatomy
Key limitation
Keep in mind: The operator remains responsible for source-image review, target confirmation, calibration, and fallback when inputs, registration, tracking, or output quality are inadequate.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Cydar EV and Cydar EV Maps support the labeled endovascular workflow by processing and displaying patient-specific vascular imaging and maps for trained procedural professionals under direct clinical control.
  • Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Peripheral vascular and endovascular anatomy Input: Supported live X-ray, vascular, or other labeled images and procedure-specific user inputs.
  • Who uses it?Intended users: Qualified interventional physicians, surgeons, radiologists, technologists, and other trained procedural staff.
  • What does the software produce?Output: Registered images, landmarks, overlays, measurements, or navigation guidance for professional review.
  • What is its most important limitation?Key limitation: The operator remains responsible for source-image review, target confirmation, calibration, and fallback when inputs, registration, tracking, or output quality are inadequate.

Clinical takeaway. Clinical role: Cydar EV and Cydar EV Maps support the labeled endovascular workflow by processing and displaying patient-specific vascular imaging and maps for trained procedural professionals under direct clinical control.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation, with particular focus on the modified features; the device passed all of the tests based on pre-determined Pass/Fail criteria. It also states the device has undergone bench testing to verify accuracy and user validation. No numeric results or data sizes are given. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Cydar EV and Cydar EV Maps support the labeled endovascular workflow by processing and displaying patient-specific vascular imaging and maps for trained procedural professionals under direct clinical control.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Image registration, fusion, localization, or procedural guidance under direct professional control.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported live X-ray, vascular, or other labeled images and procedure-specific user inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Registered images, landmarks, overlays, measurements, or navigation guidance for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital interventional, cardiovascular, operating-room, or procedure-suite workflows within the cleared indication.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified interventional physicians, surgeons, radiologists, technologists, and other trained procedural staff.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The operator remains responsible for source-image review, target confirmation, calibration, and fallback when inputs, registration, tracking, or output quality are inadequate.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports software verification and validation, with particular focus on the modified features; the device passed all of the tests based on pre-determined Pass/Fail criteria. It also states the device has undergone bench testing to verify accuracy and user validation. No numeric results or data sizes are given. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software verification and validation were conducted to establish the performance, functionality and reliability characteristics of this device, with particular focus on the modified features." … "The device has passed all of the tests beased on pre-determined Pass/Fail criteria.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports software verification and validation, with particular focus on the modified features; the device passed all of the tests based on pre-determined Pass/Fail criteria. It also states the device has undergone bench testing to verify accuracy and user validation. No numeric results or data sizes are given. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software verification and validation were conducted to establish the performance, functionality and reliability characteristics of this device, with particular focus on the modified features." … "The device has passed all of the tests beased on pre-determined Pass/Fail criteria.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K212442 FDA evidence package for Cydar EV (Series B) and Cydar EV Maps

  • DesignFDA 510(k) substantial-equivalence decision evidence and product verification described in the exact submission.
  • PopulationPeripheral vascular and endovascular anatomy
  • Scopeexact submission
  • Tested versionCydar EV (Series B) and Cydar EV Maps configuration described in K212442
  • IndependenceSponsor or vendor study

K212442

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K212442 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported live X-ray, vascular, or other labeled images and procedure-specific user inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K212442: Cydar EV (Series B) and Cydar EV Maps

  2. Routing

    Source context, not route validation: The exact FDA package describes Cydar EV, during surgery, superimposing the Pre-operative Map on a duplicated display of the X-ray fluoroscopy, and overlaying planning information onto live fluoroscopic images. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "During surgery, Cydar EV’s fusion imaging superimposes the Pre-operative Map on a duplicated display of the X-ray fluoroscopy." … "Overlay planning information such as preoperative vessel anatomy onto live fluoroscopic images, aligned based on the position of anatomical features present in both". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K212442: Cydar EV (Series B) and Cydar EV Maps

  3. AI processing

    Source context, not route validation: The exact FDA package describes Cydar EV Series B as a Software-as-a-Service product consisting only of software running on Cydar's cloud servers, accessed via standard web browser; for intra-operative fusion imaging the browser runs on an off-the-shelf client PC called the Cydar Appliance. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Unless otherwise stated, Cydar EV in this application refers to the subject device, Cydar EV Series B." … "Cydar EV is a Software-as-a-Service product and consists only of the software running on Cydar’s cloud servers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K212442: Cydar EV (Series B) and Cydar EV Maps

  4. Returned objects

    Source context, not route validation: Registered images, landmarks, overlays, measurements, or navigation guidance for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K212442: Cydar EV (Series B) and Cydar EV Maps

  5. Viewer/worklist/report

    Unresolved route: Registered images, landmarks, overlays, measurements, or navigation guidance for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K212442: Cydar EV (Series B) and Cydar EV Maps

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Cydar EV Series B as a Software-as-a-Service product consisting only of software running on Cydar's cloud servers, accessed via standard web browser; for intra-operative fusion imaging the browser runs on an off-the-shelf client PC called the Cydar Appliance. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Unless otherwise stated, Cydar EV in this application refers to the subject device, Cydar EV Series B." … "Cydar EV is a Software-as-a-Service product and consists only of the software running on Cydar’s cloud servers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes Cydar EV, during surgery, superimposing the Pre-operative Map on a duplicated display of the X-ray fluoroscopy, and overlaying planning information onto live fluoroscopic images. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "During surgery, Cydar EV’s fusion imaging superimposes the Pre-operative Map on a duplicated display of the X-ray fluoroscopy." … "Overlay planning information such as preoperative vessel anatomy onto live fluoroscopic images, aligned based on the position of anatomical features present in both". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Training
Only qualified interventional physicians, surgeons, radiologists, technologists, and other trained procedural staff should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K212442 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The operator remains responsible for source-image review, target confirmation, calibration, and fallback when inputs, registration, tracking, or output quality are inadequate.
  • Exact FDA submission
  • Checked 2026-09-04

Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K212442 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The operator remains responsible for source-image review, target confirmation, calibration, and fallback when inputs, registration, tracking, or output quality are inadequate.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K212442 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The operator remains responsible for source-image review, target confirmation, calibration, and fallback when inputs, registration, tracking, or output quality are inadequate.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. image-guidance and procedural visualization software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K212442
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Fluoroscopy/Angiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Peripheral vascular and endovascular anatomy
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-12-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K212442: Cydar EV (Series B) and Cydar EV Maps

    U.S. Food and Drug Administration - Published 2021-12-03 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K212442 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260077

OrthoGrid Hip AI® 4.0

OrthoGrid Systems, Inc.

Authorized purpose: OrthoGrid Hip AI 4.0 analyzes two-dimensional C-arm fluoroscopic images to assist positioning of hip-replacement components during direct-anterior total hip arthroplasty.

Modality
Fluoroscopy/Angiography
Anatomy
Hip
Decision
2026-05-29
FDA-cleared K252503

Intelligent NR

Canon, Inc.

Authorized purpose: Canon Intelligent NR is a noise-reduction function for fluoroscopic images acquired on compatible Canon radiography and fluoroscopy systems.

Modality
Fluoroscopy/Angiography
Anatomy
Whole body; diagnostic and interventional anatomy
Decision
2026-04-30
FDA-cleared K253269

OEC One CFD

Ge Hualun Medical Systems Co., Ltd.

Authorized purpose: OEC One CFD provides fluoroscopic and digital-spot images for adult and pediatric diagnostic, interventional, surgical, orthopedic, gastrointestinal, urologic, neurologic, vascular, critical-care, and emergency procedures, with optional trajectory guidance.

Modality
Fluoroscopy/Angiography
Anatomy
Orthopedic, gastrointestinal, endoscopic, urologic, neurologic, vascular, critical-care, and emergency anatomy
Decision
2025-11-26
FDA-cleared K243446

3DXR

GE Medical Systems SCS

Authorized purpose: 3DXR reconstructs cone-beam CT from interventional X-ray acquisitions and uses CleaRecon DL to reduce streak artifacts for display in the advanced workstation workflow.

Modality
Fluoroscopy/Angiography
Anatomy
Multi-region
Decision
2025-02-25

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history